Lakefront Receives Transparency Notification from Bank of America
Yahoo Finance ·
Lakefront Receives Transparency Notification from Bank of America Lakefront Biotherapeutics Tue, May 26, 2026 at 3:01 PM CDT 4 min read BAC LKFT Mechelen, Belgium; May 26, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant to Belgian transparency legislation 1 , Lakefront received a transparency notification from Bank of America Corporation on May 20, 2026. The notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 5% of Lakefront’ voting rights on May 13, 2026, following the acquisition of Lakefront’ voting rights and equivalent financial instruments. On May 20, 2026, Bank of America Corporation (taking into account the holding of its affiliates) owned 623,434 voting rights and 5,502,802 equivalent financial instruments, representing together 9.30% of Lakefront’ currently outstanding 65,897,071 shares. Direct voting rights after the transaction Equivalent financial instruments after the transaction Content of the notification from Bank of America Corporation: The notification dated May 20, 2026, contains the following information: • Date of notification: May 20, 2026 • Date on which the threshold is crossed: May 13, 2026 • Threshold of voting rights crossed (in %): 5% • Notification by: Bank of America Corporation • Denominator: 65,897,071 • Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities • Notified details: Merrill Lynch, Pierce, Fenner & Smith Incorporated Holder of equivalent financial instruments # of voting rights that may be acquired if the instrument is exercised The chain of control has been described at the end of the notification (section 11) and can be found here . About Lakefront ® Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X . For further information, contact Lakefront Biotherapeutics: Investor Relations Sherri Spear +1 412 522 6418 sherri.spear@lakefrontbio.com 1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time. Lakefront Receives Transparency Notification from Bank of America
AI 시장 분석
Bank of America has increased its stake in biotechnology company Lakefront Biotherapeutics, crossing the 5% threshold to hold 9.30% of its voting rights and equivalent financial instruments. This information was disclosed under Belgian transparency legislation.
상승 영향
- Biotechnology (Lakefront Biotherapeutics — Bank of America's increased stake above 5% in Lakefront Biotherapeutics can be interpreted as a positive signal regarding the biotech company's growth potential, potentially boosting investor confidence and stock price.
- Biotech (Overall) — Increased investment by a major financial institution in a biotech company can boost market confidence in the overall biotech sector, especially in oncology and immunology, potentially attracting further capital inflow.
- Financials (Bank of America) — Bank of America's increased stake in Lakefront Biotherapeutics demonstrates its efforts in diversifying its investment portfolio and identifying biotech companies with growth potential, which could contribute to long-term profitability.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 50% · Bearish (Short) 50%
595 participants
Related News
- ADARx Pharmaceuticals Seeks to Raise Funds Through 21.875 Million Share IPO at $15 to $17
- Warren Buffett's 17-Word Wisdom on Bear Markets Can Reshape Your Portfolio
- Tanker Freight Rates Surpass USD 1 Million Per Day Amid Plunging Strait of Hormuz Traffic
- Hewlett Packard Forecasts 2027 PC Volume Decline
- Global Corporate Updates and Bundesbank Economic Outlook
- Why A.P. Moller-Maersk Shares Surged Today
